文献速递心境障碍

难治性抑郁症的增效治疗:系统综述与荟萃分析

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis.
PubMed 文献 · Br J Psychiatry · 2018-11-20

该系统综述与荟萃分析纳入28项试验,评估难治性抑郁症(TRD)心理与药物增效治疗的有效性。分析显示,靶向N-甲基-D-天冬氨酸的药物效应量最高(ES=1.48,95%CI 1.25-1.71),总体药物与心理增效治疗效应量均高于安慰剂对照。尽管证据有限,多种增效治疗显示前景。

要点

  • TRD定义为至少两种抗抑郁药应答不足,纳入28项随机试验。
  • 靶向NMDA药物效应量最高(ES=1.48,95%CI 1.25-1.71)。
  • 阿立哌唑(ES=1.33,95%CI 1.23-1.44)与锂盐(ES=1.00,95%CI 0.81-1.20)证据相对较多。

核心结论

  • 尽管增效治疗在临床广泛使用,TRD的增效治疗证据仍较稀疏,但多种治疗模式显示有前景的证据。

研究设计与样本

  • 系统综述与荟萃分析,纳入28项随机试验,其中3项研究心理治疗,25项研究药物干预;采用前后对照分析评估效应量(ES)。

主要发现

  • 靶向N-甲基-D-天冬氨酸的药物效应量最高(ES=1.48,95%CI 1.25-1.71)。
  • 阿立哌唑(4项研究,ES=1.33,95%CI 1.23-1.44)与锂盐(3项研究,ES=1.00,95%CI 0.81-1.20)以外的治疗均少于3项研究。
  • 总体药物增效治疗ES=1.19(95%CI 1.80-1.30),心理增效治疗ES=1.43(95%CI 0.50-2.36),均高于安慰剂(ES=0.78,95%CI 0.66-0.91)和心理对照(ES=0.94,95%CI 0.36-1.52)。

关键数值与推荐

  • TRD定义为对至少两种抗抑郁药应答不足;纳入试验的受试者随机接受至少一种增效治疗。

临床怎么用

  • 临床可参考阿立哌唑、锂盐及靶向NMDA药物作为TRD增效治疗选项,但需注意证据基础较薄弱。

局限性

  • 前后对照荟萃分析缺乏直接比较,多数治疗研究数量少于3项,证据稀疏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Depression is considered to have the highest disability burden of all conditions. Although treatment-resistant depression (TRD) is a key contributor to that burden, there is little understanding of the best treatment approaches for it and specifically the effectiveness of available augmentation approaches.AimsWe conducted a systematic review and meta-analysis to search and quantify the evidence of psychological and pharmacological augmentation interventions for TRD. METHOD: Participants with TRD (defined as insufficient response to at least two antidepressants) were randomised to at least one augmentation treatment in the trial. Pre-post analysis assessed treatment effectiveness, providing an effect size (ES) independent of comparator interventions. RESULTS: Of 28 trials, 3 investigated psychological treatments and 25 examined pharmacological interventions. Pre-post analyses demonstrated N-methyl-d-aspartate-targeting drugs to have the highest ES (ES = 1.48, 95% CI 1.25-1.71). Other than aripiprazole (four studies, ES = 1.33, 95% CI 1.23-1.44) and lithium (three studies, ES = 1.00, 95% CI 0.81-1.20), treatments were each investigated in less than three studies. Overall, pharmacological (ES = 1.19, 95% CI 1.80-1.30) and psychological (ES = 1.43, 95% CI 0.50-2.36) therapies yielded higher ESs than pill placebo (ES = 0.78, 95% CI 0.66-0.91) and psychological control (ES = 0.94, 95% CI 0.36-1.52). CONCLUSIONS: Despite being used widely in clinical practice, the evidence for augmentation treatments in TRD is sparse. Although pre-post meta-analyses are limited by the absence of direct comparison, this work finds promising evidence across treatment modalities.Declaration of interestIn the past 3 years, A.H.Y. received honoraria for speaking from AstraZeneca, Lundbeck, Eli Lilly and Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion and Janssen; and research grant support from Janssen. In the past 3 years, A.J.C. received honoraria for speaking from AstraZeneca and Lundbeck; honoraria for consulting with Allergan, Janssen, Livanova, Lundbeck and Sandoz; support for conference attendance from Janssen; and research grant support from Lundbeck. B.B. has recently been (soon to be) on the speakers/advisory board for Hexal, Lilly, Lundbeck, Mundipharma, Pfizer, and Servier. No other conflicts of interest.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Strawbridge R, Carter B, Marwood L, et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry. 2018. PMID: 30457075. doi:10.1192/bjp.2018.233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。